What are the next steps after unsuccessful immunotherapy in RCC?
Maria Bourlon, MD, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico discusses the treatment of patients with renal cell carcinoma (RCC) after unsuccessful first-line immunotherapy (IO) consisting of either IO-IO (ipilimumab and nivolumab) or a tyrosine kinase inhibitor (TKI)-IO combinations. Certain patients with oligoprogression may benefit from localised therapies, but patients with widely metastatic disease will require a change in therapy, such as cabozantinib, as shown in the CaboPoint trial (NCT03945773). However, treatment options remain undecided after progression beyond IO-TKIs. This interview took place at the ASCO GU Cancers Symposium 2025 in San Francisco, CA. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
